Kaleido Biosciences, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Kaleido Biosciences, Inc.
Warning letter from agency for conducting clinical studies in COVID-19 patients without filing IND follows Kaleido decision the product could be designated as a food and thereby bypass an investigational new drug application.
In an interview with Medtech Insight, Sharrolyn Josse, worldwide president of VELYS Digital Surgery and Capital at Johnson & Johnson’s DePuy Synthes unit, outlines strategies that are driving the present and future VELYS robotic-assisted solution and its connected technologies.
DePuy Synthes expects its Velys robotic-assisted system to be cost-effective, easy-to-use and to be well-suited for use in ambulatory surgery centers.
Public Company Edition: Legend Biotech raised $424m in its US public market debut. Also, Pfizer commits up to $500m for equity investments and Allogene capitalizes on ASCO with a $550m offering.
- Drug Delivery
- Drug Discovery Tools